Apyx Medical Corporation revised earnings guidance for the year 2023. For the year, the company expects total revenue in the range of $53.0 million to $54.0 million, representing growth of approximately 19% to 21% year-over-year, compared to total revenue of $44.5 million for the year ended December 31, 2022. The Company?s prior guidance range for total revenue was $59.0 million to $62.0 million, representing growth of 33% to 39% year-over-year.

Net loss attributable to stockholders of approximately $16 million, compared to $23.2 million for the year ended December 31, 2022. The Company?s prior guidance for net loss attributable to stockholders was approximately $10.5 million.